Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib
Authors
Keywords
Bortezomib, Carfilzomib, Doxorubicin, Dexrazoxane, Cardiac myocytes, Topoisomerase IIβ, Cardiotoxicity, Proteasome, Chymotrypsin-like
Journal
Cardiovascular Toxicology
Volume 17, Issue 3, Pages 237-250
Publisher
Springer Nature
Online
2016-07-07
DOI
10.1007/s12012-016-9378-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib reverses pulmonary arterial hypertension
- (2016) Xinhong Wang et al. CARDIOVASCULAR RESEARCH
- Oxidative stress and proteasome inhibitors in multiple myeloma
- (2016) Brittany C. Lipchick et al. PHARMACOLOGICAL RESEARCH
- Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes
- (2016) Eva-Margarete Spur et al. TOXICOLOGY
- Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats
- (2016) Naif O. Al-Harbi TOXICOLOGY MECHANISMS AND METHODS
- A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome
- (2016) Eva M. Huber et al. Nature Communications
- Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats
- (2016) Naif O. Al-Harbi TOXICOLOGY MECHANISMS AND METHODS
- ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
- (2015) Sophia Danhof et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells
- (2015) Selin Engür et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma
- (2015) E. Wilson Grandin et al. JOURNAL OF CARDIAC FAILURE
- Bortezomib-induced acute congestive heart failure: a case report and review of literature
- (2014) Ashish Subedi et al. ANNALS OF HEMATOLOGY
- Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
- (2014) Shiwei Deng et al. BMC CANCER
- Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
- (2014) Yi Xiao et al. PLoS One
- Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition
- (2014) Sunita Maharjan et al. Scientific Reports
- The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells
- (2013) Rui Xiong et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity
- (2013) P Vejpongsa et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin
- (2012) Brian B. Hasinoff et al. Cardiovascular Toxicology
- Identification of the molecular basis of doxorubicin-induced cardiotoxicity
- (2012) Sui Zhang et al. NATURE MEDICINE
- Tearin' Up My Heart: Proteolysis in the Cardiac Sarcomere
- (2011) Andrea L. Portbury et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat
- (2011) Eugene H. Herman et al. TOXICOLOGIC PATHOLOGY
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
- (2010) Donna E. Reece et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- The role of the ubiquitin-proteasome pathway in cardiovascular disease
- (2009) C. Depre et al. CARDIOVASCULAR RESEARCH
- Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib
- (2009) Brian B. Hasinoff et al. Cardiovascular Toxicology
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition
- (2008) H. Y. Fu et al. CARDIOVASCULAR RESEARCH
- Build it up-Tear it down: protein quality control in the cardiac sarcomere
- (2008) M. S. Willis et al. CARDIOVASCULAR RESEARCH
- The use of dexrazoxane for the prevention of anthracycline extravasation injury
- (2008) Brian B Hasinoff EXPERT OPINION ON INVESTIGATIONAL DRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started